TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21611754

Group type: EXPERIMENTAL
Intervention: CpG ODN 2006
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 30
Study: 18345709

Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIa (270 microg/kg dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Activated prothrombin complex concentrate (aPCC)
Number of subjects: 0
Study: 16856619

Group type: EXPERIMENTAL
Intervention: Presence of codon 33F mutation
Number of subjects: 772

Group type: COMPARATOR
Intervention: No mutation 33F
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: Codon 33 mutations and polymorphisms
Number of subjects: 772
Study: 12762614

Group type: EXPERIMENTAL
Intervention: Pulpotomy with formocresol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pulpotomy with electrosurgery
Number of subjects: 80
Study: 10802132

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 47
Study: 9070140

Group type: EXPERIMENTAL
Intervention: Amniotic fluid index and computerised cardiotocography
Number of subjects: 500

Group type: COMPARATOR
Intervention: Maximum pool depth and computerised cardiotocography
Number of subjects: 500
Study: 8451098

Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 3663564

Group type: EXPERIMENTAL
Intervention: oral nadolol 20 mg once daily
Number of subjects: 22

Group type: COMPARATOR
Intervention: topical timolol 0.25% twice daily
Number of subjects: 22
Study: 29501682

Group type: EXPERIMENTAL
Intervention: Calorie plus numeric sodium MNI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calorie MNI only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium warning symbol
Number of subjects: 0

Group type: COMPARATOR
Intervention: No MNI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Taste intuition alone
Number of subjects: 0
Study: 28515193

Group type: EXPERIMENTAL
Intervention: Telehealthcare
Number of subjects: 1225

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1225
Study: 26624927

Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonist (GnRHa)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 24467642

Group type: EXPERIMENTAL
Intervention: rilpivirine (RPV)
Number of subjects: 1368

Group type: EXPERIMENTAL
Intervention: efavirenz (EFV)
Number of subjects: 1368

Group type: EXPERIMENTAL
Intervention: rilpivirine (RPV) and efavirenz (EFV)
Number of subjects: 1368
Study: 21875783

Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound‐guided transbronchial lung biopsy (EBUS‐TBLB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CT‐guided percutaneous needle biopsy (CT‐PNB)
Number of subjects: 0
Study: 19478340

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg body weight)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 17945069

Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 16146905

Group type: EXPERIMENTAL
Intervention: Complete multivessel treatment
Number of subjects: 69

Group type: COMPARATOR
Intervention: Culprit lesion treatment only
Number of subjects: 69
Study: 11327675

Group type: EXPERIMENTAL
Intervention: Low-Dk lenses (etafilcon A, Dk/t = 40) for up to 7 days and 6 nights
Number of subjects: 62

Group type: COMPARATOR
Intervention: High-Dk lenses (lotrafilcon A, Dk/t = 175) for up to 30 days and nights
Number of subjects: 62
Study: 9159721

Group type: EXPERIMENTAL
Intervention: Selegiline 5 mg daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Selegiline 10 mg daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Selegiline 20 mg weekly (10 mg x 2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Selegiline 10 mg weekly
Number of subjects: 24
Study: 8424292

Group type: EXPERIMENTAL
Intervention: TEA, bupivacaine 0.25% (Group 1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: TEA, bupivacaine 0.5% (Group 2)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control without TEA (Group 3)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: LEA, bupivacaine 0.5% (Group 4)
Number of subjects: 48
Study: 2462443

Group type: EXPERIMENTAL
Intervention: Gelseal aortic bifurcation graft
Number of subjects: 100

Group type: COMPARATOR
Intervention: Unsealed Dacron
Number of subjects: 100
Study: 31785201

Group type: EXPERIMENTAL
Intervention: Video-GIB
Number of subjects: 257

Group type: COMPARATOR
Intervention: GIB
Number of subjects: 257
Study: 28835153

Group type: EXPERIMENTAL
Intervention: Pentax Airway Scope (AWS)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Direct laryngoscope (Macintosh laryngoscope)
Number of subjects: 11
Study: 26056856

Group type: EXPERIMENTAL
Intervention: Individualised lower limb progressive resistance training programme (twice a week for 12 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 36
Study: 25592456

Group type: EXPERIMENTAL
Intervention: CCUE group (n=67)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Conventional group (n=63)
Number of subjects: 130
Study: 22985906

Group type: EXPERIMENTAL
Intervention: Sleep restriction (habitual bedtime minus 1.5h)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control condition (habitual bedtime)
Number of subjects: 19
Study: 20947887

Group type: EXPERIMENTAL
Intervention: LV5FU2-CDDP followed by gemcitabine
Number of subjects: 202

Group type: COMPARATOR
Intervention: Gemcitabine followed by LV5FU2-CDDP
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: LV5FU2-CDDP as first-line treatment
Number of subjects: 202

Group type: COMPARATOR
Intervention: Gemcitabine as first-line treatment
Number of subjects: 202
Study: 17767800

Group type: EXPERIMENTAL
Intervention: Isoflavones (50 mg of daidzein and genistein)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 16977291

Group type: EXPERIMENTAL
Intervention: Definitive chemoradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemoradiation and surgery
Number of subjects: 0
Study: 12651635

Group type: EXPERIMENTAL
Intervention: Tranexamic acid 30 mg/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 80
Study: 10395156

Group type: EXPERIMENTAL
Intervention: Contingency contracting-enhanced methadone detoxification
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard methadone detoxification
Number of subjects: 102
Study: 8857512

Group type: EXPERIMENTAL
Intervention: High PNG diet (1.52 mg/d of vitamin B-6, 27% PNG)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Low PNG diet (1.44 mg/d of vitamin B-6, 9% PNG)
Number of subjects: 9
Study: 1509190

Group type: EXPERIMENTAL
Intervention: Almitrine (100 mg per day)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102

Group type: COMPARATOR
Intervention: Almitrine and Placebo
Number of subjects: 102
Study: 6476299

Group type: EXPERIMENTAL
Intervention: Buprenorphin sublingual (0.4 mg.)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pentazocin i.m. (30 mg.)
Number of subjects: 40
Study: 30474740

Group type: EXPERIMENTAL
Intervention: Team handball training (HG; n=14)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Inactive control group (CG; n=12)
Number of subjects: 26
Study: 29937430

Group type: EXPERIMENTAL
Intervention: sotagliflozin 200 mg
Number of subjects: 793

Group type: EXPERIMENTAL
Intervention: sotagliflozin 400 mg
Number of subjects: 793

Group type: EXPERIMENTAL
Intervention: sotagliflozin
Number of subjects: 793

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 793
Study: 27085076

Group type: EXPERIMENTAL
Intervention: MAP‐CSBP
Number of subjects: 349

Group type: COMPARATOR
Intervention: Stan‐CSBP
Number of subjects: 349
Study: 24983260

Group type: EXPERIMENTAL
Intervention: Heparin flushing protocol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saline-only flushing protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Flushing protocols (general)
Number of subjects: 0
Study: 22128082

Group type: EXPERIMENTAL
Intervention: Azathioprine/methylprednisolone (AZA/MP)
Number of subjects: 87

Group type: COMPARATOR
Intervention: High-dose intravenous cyclophosphamide (ivCY)
Number of subjects: 87
Study: 21284283

Group type: EXPERIMENTAL
Intervention: CT gel (clindamycin phosphate 7.2% - tretinoin 0.025%) + BPO wash 4%
Number of subjects: 0

Group type: COMPARATOR
Intervention: CT gel (clindamycin phosphate 7.2% - tretinoin 0.025%) + SFC (nonmedicated soap-free cleanser)
Number of subjects: 0
Study: 17272314

Group type: EXPERIMENTAL
Intervention: Glucose-added bicarbonate solution (90 mg/dl)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Glucose-free bicarbonate solution
Number of subjects: 42
Study: 15121352

Group type: EXPERIMENTAL
Intervention: Antipsychotic continuation
Number of subjects: 7

Group type: COMPARATOR
Intervention: Taper to placebo
Number of subjects: 7
Study: 11855050

Group type: EXPERIMENTAL
Intervention: Culture school (8.5 hours)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Nursing informatics classes (8.5 hours)
Number of subjects: 94
Study: 10193252

Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 8090312

Group type: EXPERIMENTAL
Intervention: propofol + fentanyl in air/O2
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: isoflurane + fentanyl in air/O2
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: propofol + fentanyl in N2O/O2
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: isoflurane in N2O/O2
Number of subjects: 200
Study: 3192904

Group type: EXPERIMENTAL
Intervention: Endotelon (4 tablets of 50 mg per day for five weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 100
Study: 31773485

Group type: EXPERIMENTAL
Intervention: Zinc glycine chelate (ZnG) at 90 mg Zn/kg
Number of subjects: 810

Group type: COMPARATOR
Intervention: Zinc sulfate (ZnS)
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Dietary zinc supplementation (ZnG and ZnS)
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Zinc glycine chelate (ZnG)
Number of subjects: 810
Study: 30213583

Group type: EXPERIMENTAL
Intervention: Topical steroid treatment for 8 weeks
Number of subjects: 97
Study: 29157592

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 37
Study: 26164784

Group type: EXPERIMENTAL
Intervention: Needle-free powder lidocaine delivery system (0.5 mg of lidocaine)
Number of subjects: 535

Group type: COMPARATOR
Intervention: Sham placebo
Number of subjects: 535
Study: 23537980

Group type: EXPERIMENTAL
Intervention: Telemedicine (T; n = 120)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Usual care (C; n = 121)
Number of subjects: 241
Study: 21346100

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (3 mg caffeine/kg body weight)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Number of subjects: 16

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 16
Study: 19596139

Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy (IP)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Intravenous chemotherapy (IV)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: CA-125 >35 U/ml
Number of subjects: 342
Study: 15848534

Group type: EXPERIMENTAL
Intervention: Corticosteroid avoidance (CSAV) regimen
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (CsA, MMF, and CS)
Number of subjects: 109
Study: 11914258

Group type: EXPERIMENTAL
Intervention: GSNO (4.4 mmol/kg per minute)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 20
Study: 9616538

Group type: EXPERIMENTAL
Intervention: 50 micrograms salmeterol hydroxynaphthoate
Number of subjects: 12

Group type: COMPARATOR
Intervention: 200 micrograms oxitropium bromide
Number of subjects: 12

Group type: COMPARATOR
Intervention: 400 micrograms oxitropium bromide
Number of subjects: 12
Study: 7623477

Group type: EXPERIMENTAL
Intervention: Televised warnings in beer advertisements
Number of subjects: 75

Group type: COMPARATOR
Intervention: Televised advertisements without warnings
Number of subjects: 75
Study: 2793338

Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Shift in treatment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Activation level shifts
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mood modalities
Number of subjects: 15
Study: 214288

Group type: EXPERIMENTAL
Intervention: Acoustic stimuli
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Light stimuli
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Tactile stimuli
Number of subjects: 11

Group type: COMPARATOR
Intervention: No stimulus
Number of subjects: 11
Study: 30622095

Group type: EXPERIMENTAL
Intervention: Customized avatar
Number of subjects: 317

Group type: COMPARATOR
Intervention: Assigned avatar
Number of subjects: 317
Study: 27965111

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 25347021

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) sampling
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: NRT sampling
Number of subjects: 593
Study: 23997371

Group type: EXPERIMENTAL
Intervention: Eszopiclone (3 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combined eszopiclone and placebo groups
Number of subjects: 21
Study: 21993153

Group type: EXPERIMENTAL
Intervention: Brief transdiagnostic internet treatment (Wellbeing Program)
Number of subjects: 32
Study: 20186639

Group type: EXPERIMENTAL
Intervention: Implementation intentions intervention (specific walking plans every 6 weeks)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Implementation intentions intervention
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (self-monitoring daily pedometer step count)
Number of subjects: 75
Study: 16751038

Group type: EXPERIMENTAL
Intervention: Lens opacities in one or both eyes
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Previous cataract surgery included
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Visual acuity (VA) testing
Number of subjects: 700
Study: 15553105

Group type: EXPERIMENTAL
Intervention: Emedastine difumarate (2 mg b.i.d.)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Terfenadine (60 mg b.i.d.)
Number of subjects: 130
Study: 11325074

Group type: EXPERIMENTAL
Intervention: ACE inhibitor (benazepril at a dose of 2.5 mg daily)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Alphabeta blocker (arotinolol at a dose of 20 mg daily)
Number of subjects: 65
Study: 9389395

Group type: EXPERIMENTAL
Intervention: Subtotal gastrectomy
Number of subjects: 624

Group type: COMPARATOR
Intervention: Total gastrectomy
Number of subjects: 624
Study: 7956637

Group type: EXPERIMENTAL
Intervention: Normal urinary albumin excretion (UAE)
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Microalbuminuria
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Baseline UAE
Number of subjects: 481
Study: 3791141

Group type: EXPERIMENTAL
Intervention: Intensive treatment with chemotherapy and intensive meningeal radiotherapy (vincristine, actinomycin D, cyclophosphamide, Adriamycin, 4000 to 5500 rad radiation therapy, intrathecal drugs)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Preintensive treatment with chemotherapy and nonintensive meningeal radiotherapy (vincristine, actinomycin D, 4000 to 5500 rad radiation therapy)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Intensive treatment group (within group analysis)
Number of subjects: 163
Study: 28737251

Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 27780796

Group type: EXPERIMENTAL
Intervention: isafe intervention (eHealth safety decision aid)
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Online classified advertising
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Friends and family referral
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Dropout analysis
Number of subjects: 1003
Study: 24022862

Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg daily for 7 days)
Number of subjects: 34
Study: 23757053

Group type: EXPERIMENTAL
Intervention: High serum IGF‐II concentration at baseline
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: 8 SNPs from the IGF2 and H19 genes
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: SNPs rs10770063 and rs3842767
Number of subjects: 485
Study: 20733306

Group type: EXPERIMENTAL
Intervention: 2 mg RSG XR
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: 8 mg RSG XR
Number of subjects: 693

Group type: COMPARATOR
Intervention: 10 mg donepezil (control)
Number of subjects: 693

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 693
Study: 19053918

Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Enamel Matrix Derivative (EMD)
Number of subjects: 40
Study: 15911536

Group type: EXPERIMENTAL
Intervention: Surgical stabilisation of the spine
Number of subjects: 349

Group type: COMPARATOR
Intervention: Intensive rehabilitation programme
Number of subjects: 349
Study: 12135948

Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced 3D magnetic resonance angiography (MRA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: X-ray angiography (control)
Number of subjects: 32
Study: 10410527

Group type: EXPERIMENTAL
Intervention: Aquatic exercises (strengthening exercises for abdominal, gluteal, and leg muscles, stretching of the back, hip, hamstrings, and calf muscles, walking in water, and swimming)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Aquatic exercises (frequency: once a week, twice a week, or 3 or more times a week)
Number of subjects: 35
Study: 7772012

Group type: EXPERIMENTAL
Intervention: medroxyprogesterone acetate 2.5 mg daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: medroxyprogesterone acetate 5 mg daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: medroxyprogesterone acetate 10 mg daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: medroxyprogesterone acetate 2.5 mg, 5 mg, or 10 mg daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: medroxyprogesterone acetate 5 mg and 10 mg
Number of subjects: 32
Study: 2149046

Group type: EXPERIMENTAL
Intervention: Teicoplanin as first-line treatment
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Teicoplanin as second-line therapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: Piperacillin plus amikacin (initial regimen)
Number of subjects: 76
Study: 461042

Group type: EXPERIMENTAL
Intervention: Sentence that correctly labeled and described the physical arrangement of the objects
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Sentence containing the correct labels but not the correct physical arrangement
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Sentence which did not contain the correct labels and incorrectly described the physical arrangement
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control conditions providing correct labels
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control conditions omitting presentation of verbal prompts
Number of subjects: 70
Study: 31935774

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training for 4 months, consisting of awareness/stabilization, strength training, and power phases.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 14
Study: 30072155

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) for 12 weeks (3-min intervals at 40% and 80% of VO2peak, n = 17)
Number of subjects: 34

Group type: COMPARATOR
Intervention: General healthcare (GHC) for 12 weeks (n = 17)
Number of subjects: 34
Study: 27989018

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol 0.4% + propylene glycol 0.3% (PP) eye drops
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Unpreserved trehalose 3% + hyaluronic acid 0.15% (TH) eye drops
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid 0.2% (HA) eye drops
Number of subjects: 60
Study: 26154675

Group type: EXPERIMENTAL
Intervention: Web-based content refresher and complex airway management simulation
Number of subjects: 2

Group type: COMPARATOR
Intervention: Complex airway management simulation only
Number of subjects: 2
Study: 23537687

Group type: EXPERIMENTAL
Intervention: Combination therapy (solifenacin plus tamsulosin OCAS)
Number of subjects: 937

Group type: COMPARATOR
Intervention: Tamsulosin OCAS alone
Number of subjects: 937
Study: 21570188

Group type: EXPERIMENTAL
Intervention: Ivermectin (IVM)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Fenbendazole (FBZ)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 105
Study: 19274516

Group type: EXPERIMENTAL
Intervention: Combination of three disease-modifying anti-rheumatic drugs (DMARDs)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Single DMARD
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Combination of three DMARDs
Number of subjects: 162
Study: 16679098

Group type: EXPERIMENTAL
Intervention: ACE inhibitors (160 subjects receiving treatment)
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: ACE inhibitors (short duration <3 years)
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: ACE inhibitors (long duration 3 to 9 years)
Number of subjects: 745

Group type: COMPARATOR
Intervention: Non-receiving ACE inhibitors (rest of study population)
Number of subjects: 745
Study: 15599144

Group type: COMPARATOR
Intervention: Oxygen therapy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bilevel-PAP
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CPAP or Bilevel-PAP
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Oxygen therapy, CPAP, Bilevel-PAP
Number of subjects: 80
Study: 16161718

Group type: EXPERIMENTAL
Intervention: Double versus triple antiretroviral therapy
Number of subjects: 23
Study: 11079534

Group type: EXPERIMENTAL
Intervention: Citicoline (500 mg/day) for 6 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Citicoline (500 mg/day)
Number of subjects: 100